Patents by Inventor Marvin J. Meyers
Marvin J. Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230212172Abstract: Provided are compounds with the following structure: Formula (I), and methods of making and using same. The methods of using the compounds may be methods for treating or prophylaxis of a cryptosporidium infection.Type: ApplicationFiled: June 8, 2021Publication date: July 6, 2023Inventors: Christopher D. Huston, Erin E. Stebbins, Marvin J. Meyers, Edmund Oboh, Tanner Schubert
-
Patent number: 11358994Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Syndrome (SBS) are also described.Type: GrantFiled: July 25, 2018Date of Patent: June 14, 2022Assignee: Saint Louis UniversityInventors: Marvin J. Meyers, David C. Wood, Stacy D. Arnett, Matthew P. Yates, Peter G. Ruminski
-
Publication number: 20220117968Abstract: The present disclosure provides compounds, methods, and compositions which may be used to treat tuberculosis. In some embodiments, these compounds and compositions have a bactericidal property against Mycobacterium tuberculosis (Mtb). Methods of employing such agents are also provided.Type: ApplicationFiled: July 17, 2018Publication date: April 21, 2022Inventors: Marvin J. MEYERS, Megh SINGH, Christina L. STALLINGS, Leslie A. WEISS, Scott WILDMAN, Stacy D. ARNETT
-
Publication number: 20220079951Abstract: The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.Type: ApplicationFiled: December 18, 2019Publication date: March 17, 2022Applicant: Saint Louis UniversityInventors: Marvin J. MEYERS, Francis M. SVERDRUP, Timothy CALDWELL, Jonathan OLIVA
-
Patent number: 10980754Abstract: The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.Type: GrantFiled: April 19, 2017Date of Patent: April 20, 2021Assignees: SAINT LOUIS UNIVERSITY, RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: Maureen J. Donlin, John Edwin Tavis, Ryan Murelli, Marvin J. Meyers
-
Publication number: 20200297696Abstract: The present disclosure provides methods of treating a patient comprising administering a p38 inhibitor for the treatment of FSHD. In some embodiments, the present methods comprise using one or more p38 inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.Type: ApplicationFiled: November 16, 2018Publication date: September 24, 2020Applicants: Saint Louis University, Fred Hutchinson Cancer Research CenterInventors: Francis M. SVERDRUP, Stephen J. TAPSCOTT, Jonathan OLIVA, Amy E. CAMPBELL, Marvin J. MEYERS
-
Publication number: 20200190157Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Sydnrome (SBS) are also described.Type: ApplicationFiled: July 25, 2018Publication date: June 18, 2020Applicant: Saint Louis UniversityInventors: Marvin J. MEYERS, David C. WOOD, Stacy D. ARNETT, Matthew P. YATES, Peter G. RUMINSKI
-
Publication number: 20200147086Abstract: In one aspect, the present disclosure provides methods of treating a bacterial infection using an inhibitor of the nucleotidyltransferase superfamily enzyme. In some embodiments, the compounds have one of the following formulas (I), (II), (III), or (IV) wherein R1, R2, and R3 are as defined herein or a pharmaceutically acceptable salt thereof. The compounds may be used to treat a bacterial infection including an infection of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.Type: ApplicationFiled: May 16, 2018Publication date: May 14, 2020Applicants: Saint Louis University, U.S. Department of Veterans Affairs, Research Foundation of the City University of New YorkInventors: Feng CAO, John E. TAVIS, Maureen J. DONLIN, Marvin J. MEYERS, Ryan P. MURELLI, Cari ORTH, Bahaa ELGENDY
-
Patent number: 10463664Abstract: The present invention involves identification of inhibitors of herpesvirus nucleic acid metabolism. Also provided are methods of treatment using agents identified.Type: GrantFiled: November 25, 2014Date of Patent: November 5, 2019Assignee: Saint Louis UniversityInventors: John Edwin Tavis, Lynda Anne Morrison, Marvin J. Meyers
-
Publication number: 20190099385Abstract: The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.Type: ApplicationFiled: April 19, 2017Publication date: April 4, 2019Applicants: SAINT LOUIS UNIVERSITY, Research Foundation of the City University of New YorkInventors: Maureen J. DONLIN, John Edwin TAVIS, Ryan MURELLI, Marvin J. MEYERS
-
Publication number: 20160296521Abstract: The present invention involves identification of inhibitors of herpesvirus nucleic acid metabolism. Also provided are methods of treatment using agents identified.Type: ApplicationFiled: November 25, 2014Publication date: October 13, 2016Applicant: Saint Louis UniversityInventors: John Edwin TAVIS, Lynda Anne MORRISON, Marvin J. MEYERS
-
Patent number: 9353089Abstract: The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.Type: GrantFiled: March 26, 2014Date of Patent: May 31, 2016Assignees: Saint Louis University, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Xiaoping Chen, Ke Ding, Marvin J. Meyers, Micky D. Tortorella, Jing Xu
-
Publication number: 20140296532Abstract: The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.Type: ApplicationFiled: March 26, 2014Publication date: October 2, 2014Applicants: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Saint Louis UniversityInventors: Xiaoping Chen, Ke Ding, Marvin J. Meyers, Micy D. Tortorella, Jing Xu
-
Publication number: 20120035131Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.Type: ApplicationFiled: October 20, 2011Publication date: February 9, 2012Inventors: Marvin J. Meyers, Graciela B. Arhancet, Xiangyang Chen, Susan Hockerman, Scott A. Long, Matthew W. Mahoney, David B. Reitz, Joseph G. Rico
-
Publication number: 20100280016Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Inventors: Marvin J. Meyers, Graciela B. Arhancet, XiangYang Chen, Susan Hockerman, Scott A. Long, Matthew W. Mahoney, David B. Reitz, Joseph G. Rico
-
Patent number: 7781428Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.Type: GrantFiled: October 24, 2007Date of Patent: August 24, 2010Assignee: Pfizer Inc.Inventors: Marvin J. Meyers, Graciela B. Arhancet, Xiangyang Chen, Susan Hockerman, David B. Reitz, Joseph G. Rico
-
Publication number: 20100113465Abstract: Provided herein are 7-azaspiro[3.5]nonane-7-carboxamide compounds and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, cancer and cancer pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease, lupus, diabetes, allergic asthma, vascular inflammation, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.Type: ApplicationFiled: October 6, 2009Publication date: May 6, 2010Inventors: Scott A. Long, Marvin J. Meyers, Matthew J. Pelc, Barbara A. Schweitzer, Atli Thorarensen, Jane L. Wang
-
Publication number: 20080167294Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.Type: ApplicationFiled: October 24, 2007Publication date: July 10, 2008Applicant: Pfizer, IncInventors: Marvin J. Meyers, Graciela B. Arhancet, Xiangyang Chen, Susan Hockerman, Scott A. Long, Matthew W. Mahoney, David B. Reitz, Joseph G. Rico
-
Publication number: 20040209897Abstract: Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.Type: ApplicationFiled: December 19, 2003Publication date: October 21, 2004Applicant: Pharmacia CorporationInventors: William F. Vernier, David R. Anderson, Dennis P. Phillion, Marvin J. Meyers, Shridhar G. Hegde, David B. Reitz, Ingrid P. Buchler, Matthew W. Mahoney, Thomas E. Rogers, Gennadiy Poda, Megh Singh, Kun K. Wu, Jin Xie
-
Publication number: 20040152739Abstract: Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of making such compounds are described, as well as a method of using them for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.Type: ApplicationFiled: December 19, 2003Publication date: August 5, 2004Applicant: Pharmacia CorporationInventors: Cathleen E. Hanau, Serena Marie Mershon, Matthew J. Graneto, Marvin J. Meyers, Shridhar G. Hegde, Ingrid P. Buchler, Kun K. Wu, Shuang Liu, Kassoum Nacro